immune dysregulation

临床试验

计划入组 500 人 · 首次发布于 2024 年 2 月 8 日

进行中（未招募）

NCT06549114

Leniolisib for Immune Dysregulation in PIDs

计划入组 12 人 · 首次发布于 2024 年 8 月 12 日

已完成

NCT06897358

Leniolisib for Immune Dysregulation in CVID

计划入组 27 人 · 首次发布于 2025 年 3 月 26 日

药物

查看全部 421 →

Biotech

Approved

Tetanus immune globulin(Hypertet)

Acel-Immune

Biotech

Approved

Human varicella-zoster immune globulin(Varizig)

相关疾病：Varicella Zoster Virus Infection

机构

查看全部 85 →

AC Immune

Switzerland

Immune Biosolutions Inc

Canada

Immune Design Corp.

United States

资讯

查看全部 7414 →

去年

First-in-Class Monoclonal Antibody Shows Promise Against Sepsis-Induced Immune Dysregulation

2个月前

Dynamic Single-Cell Transcriptomic Analysis Reveals Immune Dysregulation in Anti-NMDAR Encephalitis

去年

临床试验

SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION

Leniolisib for Immune Dysregulation in PIDs

Leniolisib for Immune Dysregulation in CVID

药物

Tetanus immune globulin(Hypertet)

Acel-Immune

Human varicella-zoster immune globulin(Varizig)

机构

AC Immune

Immune Biosolutions Inc

Immune Design Corp.

资讯

First-in-Class Monoclonal Antibody Shows Promise Against Sepsis-Induced Immune Dysregulation

Dynamic Single-Cell Transcriptomic Analysis Reveals Immune Dysregulation in Anti-NMDAR Encephalitis

Pharming Group Initiates Phase II Trial of Leniolisib for CVID with Immune Dysregulation